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The detection of autoantibodies that target intracellular antigens, commonly termed anti-nuclear antibodies (ANA), is a serological
hallmark in the diagnosis of systemic autoimmune rheumatic diseases (SARD). Different methods are available for detection of
ANA and all bearing their own advantages and limitations. Most laboratories use the indirect immunofluorescence (IIF) assay
based on HEp-2 cell substrates. Due to the subjectivity of this diagnostic platform, automated digital reading systems have been
developed during the last decade. In addition, solid phase immunoassays using well characterized antigens have gained widespread
adoption in high throughput laboratories due to their ease of use and open automation. Despite all the advances in the field of
ANA detection and its contribution to the diagnosis of SARD, significant challenges persist. This review provides a comprehensive
overview of the current status on ANA testing including automated IIF reading systems and solid phase assays and suggests an
approach to interpretation of results and discusses meeting the problems of assay standardization and other persistent challenges.
1. Introduction
In 1950, Coons and Kaplan described the improvement of an
immunofluorescence method for the detection of antigens in
tissue cells [1]. Eight years later, Friou et al. first described
an indirect immunofluorescence (IIF) assay for the detection
of anti-nuclear antibodies (ANA) [2, 3]. Along with the
earlier discovery of the lupus erythematosus (LE) cell and
the development of the LE cell test [4, 5], this ushered in a
long and productive age of ANA testing. The ANA IIF test
initially relied on rodent tissue substrates but contemporary
tests use HEp-2 cells, a cell line established in 1952 by Moore
and her colleagues from tumors that had been produced
in weanling rats exposed to irradiation and corticosteroids
injected with epidermoid carcinoma tissue from the larynx
of a 56-year-old male [6]. In the following decades, ANA
tests using HEp-2 cells revolutionized the diagnosis of ANA
associated rheumatic diseases (AARD) including systemic
lupus erythematosus (SLE), systemic sclerosis (SSc), Sjo¨gren’s
syndrome (SjS), mixed connective tissue disease (MCTD),
and idiopathic inflammatory myopathies (IIM) [7, 8].
The IIF assay on HEp-2 cells has been replaced in
many laboratories since the development of ANA screening
assays based on ELISA and automated, high throughput
multiplex assays using addressable laser bead and other
array technologies for the detection of specific ANA [9,
10]. Due to a significant prevalence of “false negative”
ANA results on these newer platforms and an insufficient
communication between laboratorians and clinicians, there
have been growing concerns about unilateral adoption of
these newer screening and high throughput assays [11].
Questions about which method should be used and the
lack of standardization of the novel test algorithms led
the American College of Rheumatology (ACR) to form
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Table 1: Statistical terms relevant for ANA testing.
Statistical measure General explanation Implication for ANA
Sensitivity Statistical measure of how accurately a testcorrectly identifies diseased individuals
ANA is used as screening test. High sensitivity is
important. The sensitivity for different AARD
varies (i.e., higher in systemic lupus
erythematosus versus myositis)
Specificity Statistical measure of how well a test correctlyidentifies absence of the disease in question
Importance of specificity depends on pretest
probability. In settings with low pretest
probability, high specificity is required.
Diagnostic efficiency Combination of sensitivity and specificity Not commonly used
False negative (clinically) Negative test result of a diseased individual
ANA is used as screening test. False negative
results are undesirable. However, in all AARD,
patients without a positive ANA test exist.
Therefore, a negative result should never be used
to rule out AARD.
False positive (clinically) Positive test result of an individual without thedisease in question
In case of low pretest probability, false positive
results significantly impact the posttest probability
False negative (analytically) Negative test result in the presence of therespective analyte See negative positive (clinically)
False positive (analytically) Positive test result in the absence of therespective analyte See false positive (clinically)
Positive predictive value Ratio of true positive to combined true andfalse positives. Depends on the prevalence (pretest probability)
Negative predictive value Ratio of true negatives to combined true andfalse negatives. Depends on the prevalence (pretest probability)
Positive likelihood ratio
The probability of a positive test results in
patients with the disease divided by the
probability of a positive test result in
individuals without the disease. Independent
from prevalence.
#Important information for clinicians. Should be
included in the laboratory report together with an
explanation of its significance in the context of the
test result.
Negative likelihood ratio
The probability of a negative test result in
patients with the disease divided by the
probability of a negative test result in
individuals without the disease. Independent
from prevalence.
#Important information for clinicians. Should be
included in the laboratory report together with an
explanation of its significance in the context of the
test result.
#The importance of the likelihood ratio in the laboratory report is controversially discussed, but might improve use of ANA test results in the future.
a task force who recommended the use of the conventional
IIF HEp-2 platform for ANA detection [12]. This recom-
mendation was, in part, based on evidence that the HEp-
2 cell substrates are essentially an “array” presenting >100
autoantibody targets whereas most high throughput screen-
ing arrays are much more limited in autoantibody target
composition. This has prompted a reevaluation of the ANA
IIF method which was reflected by entire sessions dedicated
to HEp-2 ANA testing at international clinical and scientific
meetings.
In recent years, the first digital imaging systems for ANA
IIF have been developed which eliminate some major draw-
backs of the method, namely, the subjectivity of observers
reading the slides and the lack of an automated proce-
dure [15–17]. Nevertheless, several drawbacks of the HEp-
2 IIF methods persist and other technologies for ANA
detection continue to emerge and evolve. In this review,
novel insights and updates on ANA detection are pre-
sented and the pros and cons of different methods are
discussed.
2. Statistical Considerations
2.1. Sensitivity and Specificity. For diagnostic applications,
it is important to differentiate between analytical sensitiv-
ity/specificity and clinical (diagnostic) sensitivity/specificity.
Therefore, the terms clinical sensitivity and specificity, false
negative, false positive, and predictive values are described
in Table 1. In addition, it is widely known and extensively
documented that certain autoantibodies can precede the
diagnosis or full clinical expression of an underlying disease
for many years and thus false positive results at a given point
in time might, over a subsequent time period, become a true
positive [18, 19]. Consequently, the term “false positive” for
autoantibodies needs to be used carefully.
2.2. ROC Analysis and Cut-Off Selection. The receiver oper-
ating characteristic (ROC) analysis has a broad range of
applications and was first used for military purposes during
World War II [20]. In medicine, ROC analysis has been
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Figure 1: Illustration of pretest and posttest probability. Posttest probability (predictive value) for systemic lupus erythematosus as a function
of pretest probability and as a function of indirect immunofluorescence (IIF) and solid phase assay (SPA) (EliA CTD screen,Thermo Fisher)
test result. Values for likelihood ratios are from Bossuyt and Fieuws [31], WBC = white blood cell.
extensively used for diagnostic testing to evaluate the effec-
tiveness of a novel diagnostic method as compared to an
already established one or so called “gold standard” method.
Several statistical methods can be applied using the ROC
analysis including the most commonly used area under the
curve (AUC).TheAUC is equivalent to theMann-Whitney𝑈,
which tests for themedian difference between scores obtained
in the two continuous data sets. However, any attempt to
summarize the ROC curve into a single number fails as
information about the pattern of tradeoffs of the particular
discriminator algorithm is not expressed.
The manner by which immunoassay cut-offs are estab-
lished varies significantly among researchers and scientists in
diagnostic companies. A common approach to define the cut-
off value for certain assays is to test specimens from patients
with the respective disease and compare them to a broad
range of controls including related and unrelated diseases
as well as age and gender matched (apparently) healthy
individuals. The mean value plus 3-fold standard deviation,
the 95% or the 99% percentile, of the controls are then often
used to define the cut-off value. Another popular approach
for definition of the cut-off value makes use of ROC analysis.
Despite broad application, most references do not specify
how to use the ROCanalysis to define the cut-off value [21]. In
the majority of cases, a visual approach is used to identify an
appropriate point on the ROC curve which provides a good
combination of sensitivity and specificity. Following this, it is
important that the cohort used to define the cut-off (training
set) is large enough to achieve statistical power and that the
cut-off is validated using an independent cohort of patients
(validation set).
The method used for cut-off definition strongly depends
on the assay and how it is intended to be used in a routine
setting. For a screening assay, a high degree of sensitivity is
mandatory to ensure that the number of patients that are
missed by the assay is kept as low as possible. In contrast,
confirmation tests need high specificity. In general, low cut-
off values increase the sensitivity at the expense of decreasing
specificity and vice versa when a higher cut-off is defined
[9, 10].
The interpretation of the ANA test results depends on the
pretest probability of having the disease or whether fulminant
disease is present. In a setting of high index of suspicion, even
low titers of ANA-IIF can be interpreted as significant [22].
In 1997 it was suggested by Tan and colleagues [23] that the
test should be performed and reported at two dilutions, 1 : 40
and 1 : 160, in order to preserve the appropriate sensitivity and
specificity. A more recent study recommended using a more
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economical single screening dilution of 1 : 160 [24] which was
confirmed by a recommendation paper that used a Delphi
approach for assessment of autoantibodies to intracellular
antigens [21]. ANA-IIF testing on HEp-2 cells is currently
widely accepted as the procedure of choice for the detection
of ANA but not as a corollary of disease activity or relapse
[21].
2.3. Likelihood Ratio. In clinical practice, an important and
relevant question is “What is the probability of a patient
having a particular disease when the laboratory test is
positive or not having the disease when the laboratory test is
negative?” [25]. Clinicians and laboratory professionals have
difficulties in estimating the posttest probability for a disease
based on sensitivity and specificity (2). Likelihood ratio (LR)
is an alternative, and probably more easily understood, way
to convey diagnostic accuracy data in a clinical setting [26].
The LR for a disease is the probability of the test result
in patients with the disease divided by the probability of
the same test result in individuals without the disease. The
posttest probability for disease associated with a particular
test result can be estimated based on the pretest probability
and the LR for that particular test result [25, 27].
Traditionally, a single cut-off is used for the interpretation
of a laboratory test and all values above or below the cut-
off value are given the same interpretation (positive or
negative, resp.). For many AARD, the likelihood for disease
increases with increasing antibody concentration [28–30].
This information is lacking when a single cut-off is used. LR
can be assigned to a particular test result or to a test result
interval (e.g., the antibody titer of ANA). It has been shown
that the LR for an AARD increases with increasing antibody
levels [28]. Knowledge of test result (interval) specific LR
improves the clinical interpretation of a particular test result
compared to knowledge related to a single cut-off value.
The LR gives an estimation of whether there will be a
significant change in pretest to posttest probability of disease
given the test result [25]. A LR of 1 implies that there will be
no difference between pretest and posttest probability [25].
LRs >10 or <0.1 indicate large, often clinically significant,
differences. LRs between 5 and 10 and between 0.1 and 0.2
indicate modest clinical differences [25].
The LR for SLE for ANA by IIF has been estimated to
be 7 for a positive test result and 0.03 for a negative test
result, whereas the LR for SLE based on solid phase assays
(SPA) [in this case: Fluoro enzyme immunoassay (FEIA),
EliA CTD screen] has been estimated to be 24 for a positive
test result and 0.27 for a negative test result [31]. Using LRs,
one can calculate the posttest probability for any given pretest
probability [25]. Figure 1 illustrates a graphical representation
of the posttest probability (predictive value) for SLE as a
function of the pretest probability for IIF as well as for
SPA. Such graphical representation has been shown to be a
convenient way to convey diagnostic information [26].
To illustrate the impact of pretest probability and assay
performance on the posttest probability clinical examples are
provided (unpublished data, based on expert experience of
Pier-Luigi Meroni).
Table 2: Anti-nuclear antibodies (ANA) in different ANA associ-
ated autoimmune rheumatic diseases and healthy individuals.
Antibody AARD
SLE SSc SjS IIM MCTD HI
dsDNA 40–70% <3% <3% <3% <3% <3%
Chromatin 40–70% <3% <3% <3% 5–18% <3%
RNP 10–40% 5–15% <3% 5–15% 100%5 <3%
Sm 5–20% <2% <1% <1% <2%2 <1%
SS-A/Ro60 40–70% 3–10% 60–90% <3% <3% <3%
Ro52/
TRIM21 40–70% 15–30% 70–90% 25–50% <3% <3%
SS-B/La 15–30% 1–5% 60–80% 5–15% <3% <3%
Scl-70 (topo I) 0–5% 20–40%4 <3% <3% <3% <1%
Jo-1 1–3% 1–3% <2% 15–30% <2% <1%
Centromere 2–5% 20–40%4 5–10% 1–3% 2–5% <3%
RNA Pol III <1% 5–25%4 <1% <1% <1% <1%
Ribosomal P 10–30% <2% <2% <2% <2% <1%
PM/Scl 1–3% 5–10% <2% 5–10% <2% <3%
Mi-2 <1% 3–8% <1% 5–15%1 <1% <3%
Ku 5–20% 3–8% <3% 3–10%3 <3% <3%
PCNA <5% <1% <1% <1% <1% <3%
Th/To <1% 3–10% <1% <1% <1% <1%
1Rare in PM, higher prevalence in DM; mild form of disease; early during
development.
2Prevalence depends if antigen contains SmBB󸀠 (cross-reactive with RNP).
3Very high titer in PM.
4Anti-Scl-70, anti-centromere, anti-RNA Pol III antibodies tend to be
mutually exclusive.
5Part of the classification criteria, therefore should be 100%; however,
depending on assay used, some patients might be negative.
Note: Prevalence values were established based on literature and consensus
of authors.
Abbreviations: DM: dermatomyositis; IIM: idiopathic inflammatory myopa-
thy (polymyositis/dermatomyositis); MCTD: mixed connective tissue dis-
ease; PCNA: proliferating cell nuclear antigen; PM: polymyositis; RA:
rheumatoid arthritis; RNA pol III: RNA polymerase III; RNP: ribonu-
cleoprotein; Sm: Smith antigens (U2-U6 RNP); SjS: Sjo¨gren’s syndrome;
SLE: systemic lupus erythematosus; SPA: Solid phase assay; SSc: systemic
sclerosis; TRIM: tripartite motif.
For example, a young woman with hair loss and pol-
yarthralgias, which are very nonspecific signs of SLE, is
estimated to have a pretest probability for SLE of 1%. If ANA
by IIF turns out to be positive in this patient the probability
for SLE increases from 1% to 6%, which is still low. If the SPA
CTD screen reveals an autoantibody directed to a specific
nuclear antigen (ENA or dsDNA), then the probability for
SLE is higher (19%). A second example is a young woman
who presents to her physician with photosensitivity and mild
leucopenia (3000–3500WBC/mm3). Based on this clinical
presentation, the probability for SLE is estimated to be 10%.
A positive ANA by IIF increases the probability for SLE
to 42%, whereas a positive SPA CTD screen increases the
probability for SLE to 72%, which makes the diagnosis for
SLE likely. However, a woman positive for anti-SSA/Ro could
display the same clinical manifestations not necessarily hav-
ing SLE (sometimes the sicca syndrome is clinically silent at
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the beginning of a primary SjS). A negative ANA by IIF result
would reduce the probability for SLE from 10% to <1%. The
third example is a young woman with photosensitivity, malar
rash, and symmetrical polyarthritis. This clinical picture is
suggestive of SLE (50% probability). A positive IIF result
increases the probability for SLE from 50% to 87%, whereas a
positive SPA CTD screen increases it to 96%. A negative IIF
result would reduce the probability for SLE to 7%, whereas a
negative SPA test result would reduce the probability of SLE
to 21%, illustrating the NPV of SPA is lower than the NPV of
IIF.
3. Nomenclature of Antibodies to
Cellular Antigens Commonly Referred to
as Anti-Nuclear Antibodies (ANA)
Historically, only antibodies targeting antigens present in the
nuclear compartment of the cells (nuclear antigens) were
called ANA. Similarly, the term extractable nuclear antigen
(ENA), described in 1959 by Holman and Robbins was used
for a group of nuclear antigens extractable by saline solutions
[14]. Nowadays, with the identification of a variety of new
autoantigens within various compartments of the cell, the
nomenclature has become rather imprecise and misleading
[21]. As an oversimplification, even serum samples with anti-
cytoplasmic but without ANA reactivity are sometimes con-
sidered as ANA positive [32–34].This confusing terminology
has even been adopted in the nomenclature of commercial
autoantibody assays and kits. Autoantibody arrays on various
technology platforms are often termed as ANA or ENA
profiles even though they contain relatively insoluble nuclear
antigens such as dsDNA and/or cytoplasmic targets such as
ribosomal P or Jo-1 antigens. Therefore, standardization of
this nomenclature is highly desirable.
4. Anti-Nuclear Antibodies in
Different Conditions
To date, more than 160 autoantigens, many of them localized
to the cell nucleus, have been described in sera of SLE patients
[35]. Therefore, the spectrum of SLE associated autoantigens
contained in most ANA screening SPA includes only a small
proportion of antigens targeted by SLE autoantibodies [35,
36]. However, most SLE associated autoantigens, apart from
the standard ENAs, are rarely the target of individual SLE
sera and even more uncommon without reactivity to any
of the standard ENAs. For example, a recent study found a
sensitivity of a SPA for SLE of 79% (in diagnostic samples)
compared to a sensitivity of IIF at cut-off 1 : 160 of 90%
[29]. Thus, the number of SLE patients having at least one
clinically meaningful autoantibody that are missed by ANA
SPA appears to be approximately 10%. In contrast, an even
larger proportion of SSc patients have a negative test results
when an ANA SPA is used [37]. Consequently, the clinical
utility of novel assays for different AARD can be different and
each new assay has to be validated in all AARD subgroups
(SLE, SSc, MCTD, SjS, and IIM).
In addition to SLE and SSc, ANA can be found in
various other SARD including but not limited to IIM, SjS,
and MCTD (Table 2). The appreciation that ANA are useful
diagnostic biomarkers in a broad spectrum of autoimmune
conditions has led to a significant change in the referral
pattern of ANA tests to diagnostic laboratories (see Figure 1).
Historically, primarily rheumatologists and clinical immu-
nologists ordered ANA testing as an aid to the diagnosis of
SLE. Much of this was due to the embedding of ANA and
certain ENA in the older and now more recent classification
criteria for SLE [38, 39]. Nowadays, a wider spectrum
of clinicians order the ANA test (see Figure 1) including
but not limited to internists, dermatologists, nephrologists,
oncologists, cardiologists, neurologists, gastroenterologists,
otolaryngologists, ophthalmologists, gynecologists, and even
primary care physicians (Figure 2). This can be attributed to
the broadening spectrum of ANAs in rheumatoid arthritis
(RA), antiphospholipid syndrome (APS) [40], autoimmune
liver diseases such as autoimmune hepatitis and primary
biliary cirrhosis (PBC) [41–46], vasculitis [47], inflammatory
bowel disease (IBD) [48–51], and cancer [52–57] (Table 4).
5. Differential Diagnosis of
Autoimmune Diseases
The early and accurate diagnosis of autoimmune diseases
can be very challenging because the spectrum of signs and
symptoms are verywide and often overlap. Initially, anAARD
has to be differentiated from a wide spectrum disorders
(i.e., infections, malignancies, allergic, and adverse drug
reactions) presenting with similar signs and symptoms. For
example, a patient suspected to have SLE can first present
with skin manifestations which need to be differentiated
from discoid lupus, polymorphous light eruption, rosacea,
drug eruptions, and other dermatoses. If other organs are
involved (i.e., kidney, lung, musculoskeletal, cardiovascular,
or neuropsychiatric [58]) the differential diagnosis must take
other diagnostic possibilities into consideration. Secondly,
after the presence of an AARD is confirmed on the basis
of signs, symptoms, and physical examination, the different
AARD need to be differentiated from each other so as to
assist the clinician with decisions about appropriate ther-
apeutic interventions. This can be further complicated by
the evolution of autoimmune diseases from one condition
to another. Many AARD, especially SLE, can present with
arthritis but during follow-up, a diagnosis of RA or “rupus”
might be established [59, 60]. Similarly, MCTD can evolve
into SSc or RA. The appropriate interpretation of a positive
or negative ANA can help enlighten the diagnostic and
prognostic accuracy of AARD, although very little is known
about the LR to differentiate the different diseases.
6. Screening and Profile Assays for
ANA Detection
6.1. ANA by Indirect Immunofluorescence on HEp-2 Cells. For
well over the last decade, the IIF HEp-2 assay was being
replaced by newer technologies for the detection of ANA [61]
Journal of Immunology Research 7
Rheumatology
Clinical immunology
Internal medicine
Dermatology
Primary care
Hematology
Nephrology
Oncology
Cardiology
Obstetrics and 
gynecology
Neurology
Gastroenterology
…1960 Today…
Pretest probability decreased → significant consequences on posttest probability
Figure 2: Change in referral patterns. Historically, when the ANA HEp-2 test became available in around 1960 exclusively rheumatologist
and clinical immunologists ordered the ANA test. With the emerging recognition that many other diseases are associated with ANAs, a
broad range of clinical disciplines order the ANA test. With changes in the ANA referral pattern and the associated decrease in the pretest
probability, the posttest probability significantly decreases (indicated by the triangle).
Table 4: Clinical utility of ANA testing in different diseases.
Diagnosis Clinical utility ANA prevalence Monitoring/prognosis Comments
SLE Very useful 90–95% Not useful ANA IIF superior to ANA solid phase assays
SSc Very useful 85–95% Not useful ANA IIF superior to ANA solid phase assays
SjS Useful 50–60% Not useful ANA solid phase assays superior to ANA IIF; SS-Areactivity can be missed by ANA HEp-2
AIM Somewhatuseful 50–60% Not useful
ANA solid phase assays superior to ANA IIF; Jo-1
reactivity can be missed by ANA HEp-2
MCTD Very useful 90–100% Not useful High titer anti-U1-RNP are highly indicative forMCTD
JCA/JIA Somewhatuseful 50–60% Very useful
Useful for subset that are at risk of developing uveitis
PBC Very useful 50–80% Not proven
ANA IIF superior to solid phase assays; Antibodies
to SP100, gp210, nucleoporin p62, lamin B receptor
and Ro52 /TRIM21. Anti-gp210 reported association
with poor prognosis.
RA Not useful 15–20% Not useful
Homogeneous and speckled staining are the most
common patterns
APS Not useful 40–70% Not useful
Might indicate systemic autoimmunity in primary
APS patients
AT Not useful 10–20% Not useful
Higher in Grave’s disease as compared to
Hashimoto‘s thyroiditis
Cancer and
paraneoplastic
syndromes
Not useful, or
utility not
established
20–50% Not useful
Antibodies to CENP-F and to other proteins might
be useful to help in the diagnosis of cancer; p53 has
been discussed; not many systematic studies on
ANA in cancer
AIH Useful 40–80% Not useful Prevalence depends on phase of the disease
Abbreviations: AIH: autoimmune hepatitis; AIM: autoimmune inflammatory myopathy (polymyositis, dermatomyositis); APS: anti-phospholipid syndrome;
AT: autoimmune thyroiditis; JCA/JIA: juvenile chronic arthritis/juvenile inflammatory arthritis; MCTD:mixed connective tissue disease; PBC: primary biliary
cirrhosis; RA: rheumatoid arthritis; SjS: Sjo¨gren’s syndrome; SLE: systemic lupus erythematosus; SSc: systemic sclerosis NOTE: Prevalence values are based on
diagnostic samples (not treated patients).
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Table 5: Advantages and disadvantages of the HEp-2 ANA test.
Advantages Disadvantages
Variety of different target autoantigens (>100) Subjectivity
Some autoantibodies can be identified without
confirmatory testing (i.e., anti-centromere)
Poorly standardized across manufacturers
Discovery tool for novel autoantibodies Requires training and expertise
Useful for a spectrum autoimmune diseases (i.e.,
autoimmune hepatitis)
Low sensitivity for certain clinically important
autoantibodies (i.e., Jo-1, ribosomal P, SS-A/Ro60,
Ro52/TRIM21)
Low specificity (high false positive rate)
Table 6: Overview of defined ANA patterns (modified from Wiik
et al., 2010 [13]).
Pattern group Pattern
Nuclear envelope
(membrane)
Smooth nuclear envelope
Punctate nuclear envelope
Nuclear
Homogeneous pattern
Large speckled
Coarse speckled
Fine speckled
Fine grainy Scl-70-like
Pleomorphic speckled (i.e., PCNA)
Centromere
Multiple nuclear dots
Coiled bodies (few nuclear dots)
Dense fine speckled
Isolated metaphase chromosomes
Nucleolar
Homogeneous nucleolar
Clumpy nucleolar
Punctate nucleolar
Mitotic spindle
apparatus
Centriole (centrosome)
Spindle pole (NuMa) (MSA-1) (HSeg5)
Spindle fiber
Midbody (MSA-2)
CENP-F (MSA-3)
Cytoplasmic
Diffuse
Fine speckled
Mitochondrial
Discrete dots: GW bodies,
endosomes, lysosomes
Golgi complex
Intercellular contact proteins
Fibers and cytoskeleton
Rods and rings
Negative
and several larger laboratories switched to automated high-
throughput immunoassay platforms [61]. However, in 2010, a
position paper was published indicating that IIF on HEp-2
cells should remain the “gold standard” for the detection
of ANA [12], triggering a renaissance of the IIF ANA test.
Nevertheless, in some cases, an ANA result based on IIF
ANA on HEp-2 substrates may mislead the clinician and has
to be interpreted within the clinical context [62] (Table 5).
In addition, standardization of this assay is difficult due to
intermanufacturer variations in the substrate and the fixation
process, characteristics of the secondary antibody used [63],
interlaboratory variations in microscopy apparatus, and,
especially, the subjective interpretation of the results [64].
Detection of ANA by IIF may also yield false negative results
even in the presence of high titers of antibodies, such as those
directed to SS-A/Ro60, Ro52/TRIM21, Jo-1 (histidyl tRNA
synthetase), and others [65–67]. Additionally, the challenge
of significant variation of staining patterns on the ANA
HEp-2 IIF substrates obtained with slides from different
manufacturers [63] has led to a proposed nomenclature for
IIF patterns [13] (Table 6). For these reasons, considerable
effort has been dedicated to the development of standardized
SPA for routine use, such as ELISA [68], which are attended
by guidelines for the detection of ANA [21, 62, 69].
6.1.1. Automated Pattern Recognition of the ANA HEp-2 Test.
Computer assisted pattern recognition for ANA testing on
HEp-2 cells has been described more than ten years ago [70].
Automated hardware and software-based pattern recognition
platforms that allow for the identification and archiving of
IIF patterns obtained on HEp-2 cell substrates; however, they
have only become available during the last few years [15,
16, 71–74]. The operating principle of these new automated
systems is acquiring, storing, and analyzing of digital images
of stained IIF slides and displaying them on high resolution
computer monitors. The inherent technical difficulties of
processing and reading IIF slides (manual reading, real-time
interpretation, need for dark room, and handwritten results
transcription) make traditional IIF methods difficult to fit in
the workflow of modern, automated laboratories. The new
automated systems are powerful workflow and operational
tools that can eliminate the need for a darkroom and separate
image acquisition from image interpretation and have the
potential to improve the quality and utility of the ANAHEp-2
assay.
The currently available automated ANA IIF image ana-
lyzing systems include NOVA View (INOVA Diagnostics,
San Diego, US) [30], Aklides (Medipan, Berlin, Germany)
[15, 16, 75], G-Sight (Menarini, Florence, Italy) [76, 77],
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EuroPattern (Euroimmun, Lu¨beck, Germany) [73], Image
Navigator (ImmunoConcepts, Sacramento, US), and Helios
(Aesku, Wendelsheim, Germany) (Table 7). The systems dif-
fer from each other with respect to the use of DNA-binding
counterstains, such asDAPI, the cell substrate used (e.g.,most
systems are restricted to using the respective manufacturer’s
slides), the throughput, the number of patterns that can be
identified, and user-friendly features of the software [76, 77].
Generally, these automated systems are based on amicro-
scope fitted with an automated stage, a CCD digital camera,
a LED light source, and software that controls the moving
parts and directs image acquisition. All systems perform
some kind of fluorescent light intensitymeasurement and use
the results for preliminarily categorization of the samples as
positive or negative and for pattern analysis. The automated
reading is followed by human visual interpretation of the
digital images that are displayed on a computer monitor,
allowing user confirmation or revision of the automated
results. By providing good quality digital images and other
objective information (such as preliminary classification and
pattern interpretation), these automated systems support
the operators’ decision making and increase the consistency
between readers and readings. In addition, the digital images
can be stored for training, documentation, follow-up, and
second opinion purposes. In the future, these digital images
might also become part of the patient’s electronic medical
record (EMR). At present, the systems are highly reliable in
their ability to discriminate positive from negative reactions
and to estimate fluorescence intensity, but the accuracy and
robustness of pattern recognition does not reach the accuracy
of human interpretation [77, 78]. An important feature is, the
quality of the digital images, enabling the operators to make
the same clinically relevant interpretation as theywouldmake
using a conventional microscope.
The final result interpretation is made by the opera-
tor, therefore subjectivity cannot be completely removed.
Moreover, the characteristics of the HEp-2 substrates and
conjugates influence the appearance of certainANA specifici-
ties, and the automated pattern identification of the various
systems is likely based on somewhat different programming
principals. Nevertheless, automated systems for ANA HEp-
2 analysis are a significant step forward to reduce variability
and offer opportunities to increase harmonization of ANA
interpretation [79].
Some systems offer automated assessment of ANA end-
point titers on a single serum dilution, thereby eliminating
the need for serial dilutions [75].Moreover, the potential inte-
gration of the automated digital IIF systems with laboratory
information systems (LIS) provides sample traceability, and
eliminates manual transcription and associated transmittal
errors, thereby improving patient safety. The systems also
hold the promise to reduce hands on time. Work flow studies
using different systems are required to analyze the efficiency
benefits of those systems.
6.1.2. Limited Sensitivity and Specificity of ANAHEp-2 IIF Test.
Several studies have demonstrated limited analytical/clinical
sensitivity [61, 63, 66, 80, 81] and clinical specificity [82–85],
of IIF on HEp-2 cells. In particular for anti-Rib-P, anti-
SSA/Ro60, and anti-Jo-1 autoantibodies, the ANA HEp-2 IIF
test has been reported to lack analytical sensitivity which
translates to the clinical sensitivity for AARD [63, 65, 66, 81,
86, 87]. In a comparative analysis of an ANAELISA andANA
IIF, equivalent sensitivity but significantly higher specificity
of the ELISA was observed [84]. When using the cut-off
recommended by the manufacturer, the clinical specificity of
IIF for AARD was as low as 62.3% [84].
Based on these observations, over three decades ago a
transfected HEp-2 cell line overexpressing SS-A/Ro60 was
developed and this cell-based IIF assay is marketed as HEp-
2000 cells [81, 88–90]. A similar approach has recently been
used for SmD1 antigen in a research HEp-2 cell line [91].This
technological approach of overexpressing target antigens in a
variety of cell lines has more recently become a productive
approach to cell based IIF assays where structural or con-
formational epitopes are important for human autoantibody
detection. It was found that adding antigen specific assays
to IIF on HEp-2 cells significantly improved the diagnostic
algorithm for the diagnosis of SARD [92]. However, it was
concluded in this study that changing from IIF to other
methods for ANA detection also requiredmodification of the
disease criteria. In addition, it was highly recommended to
use anti-SS-A antibody assays in addition to ANAHEp-2 test
[92].
6.2. Different Staining Patterns Have Different Specificities.
Disease classification criteria, such as the SLE criteria [38,
39], do not distinguish between different ANA IIF patterns.
Although certain ANA patterns on HEp-2 cells have a signif-
icant disease associations, in clinical practice differentiation
of IIF patterns is rarely used as an aid in establishing the
clinical diagnosis [21]. Nevertheless, it is well established
that the centromere staining pattern is primarily associated
with the limited cutaneous form of SSc (also referred to
as the CREST syndrome) [8, 93]. Additional examples are
the association of the homogenous IIF pattern with SLE
and nucleolar IIF pattern with SSc [37], although these
generalizations have not been observed in all studies [94]
(most likely attributed to different pretest probabilities).
Interestingly, antibodies to dense fine speckled 70 (DFS70),
also known as LEDGF (lens epithelium-derived growth
factor), which generate a DFS IIF pattern on HEp-2 cells
were not commonly observed in AARDs [82, 95–102]. These
antibodies decorate interphase nucleoplasm outside of the
nucleolus but in contrast to the anti-SSA/SSB and anti-
Mi-2 antibodies, the anti-DFS70/LEDGF antibodies stain
the metaphase and telophase chromosomal cell plates [13]
(Figure 3). Just recently, it was confirmed that theDFS pattern
was not associated with AARD and was primarily found in
apparently healthy individuals [103]. In rare cases, this pattern
can also be observed in patients with AARD, but these cases,
anti-DFS70 antibodies are commonly accompanied by other
autoantibodies [98, 102]. Follow-up of individuals with high
titers of anti-DFS70 antibodies revealed that they retain ANA
reactivity even after four years but do not develop SARD
[103, 104]. Hence, it has been suggested that, within some
Journal of Immunology Research 11
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(b)
(c)
Figure 3: Characteristic staining pattern of anti-DFS70 antibodies.The characteristic dense fine speckled (DFS) staining pattern of interphase
HEp-2 cells is indicated by the blue arrow and the strong chromatin staining of mitotic cells by the red arrow. (a) Wide field view using 40x
magnification, (b) dense fine speckled pattern of an interphase nucleus, and (c) of the metaphase chromatin of a mitotic cell.
limits, anti-DFS70 antibodies can be used to exclude the
diagnosis of AARD [82]. The major epitope of the molecule
is conformation dependent and is located in the C-terminal
part of the molecule [105]. Although the immunoreactive
region has been shown to be located within a stretch of 22
amino acids (407–435), the use of 12 mer peptides failed to
establish reactivity with the presumed linear epitope [105].
6.3. ANA Screening ELISA. During the last decade, differ-
ent strategies have been utilized to develop, evaluate, and
commercialize several ANA screening ELISAs [106–110].The
majority of ANA screening ELISAs make use of mixtures or
“blends” of purified autoantigens from native sources and/or
recombinant technologies [106, 111].The composition of these
antigen preparations is quite diverse and is dependent on
several factors including the availability of pure antigens and
the technical feasibility of combining all different antigens
in a single assay. Most available immunoassays contain SS-
A/Ro60 [112], SS-B/La, Scl-70/topoisomerase I [113], CENP-
B [93], Jo-1, U1-RNP, Sm, and dsDNA [114]. ANA screen-
ing ELISAs from some manufacturers also contain other
autoantigens such as PM/Scl or ribosomal P [36]. However,
based on comparison to immunoprecipitation of radiola-
belled native proteins and other techniques, reactivity can be
missed by these ELISAs even if the autoantigens are contained
in the mixture [36]. This can be attributed to the notion
that individual autoantigens exhibit different biochemical
properties and, therefore, display different binding behaviors
when solid phase matrices are used to bind the target
autoantigens. For example, some antigensmight bind to other
targets in the same mixture resulting in a masking effect that
gives the impression that insufficient epitopes are available for
human autoantibody binding. Some antigens, such as PCNA
[115, 116], RNAPol III [117], orTh/To [118], are rarely included
as purified antigen in screening assays.
6.4. Line Immunoassays. Line immunoassays (LIA) can basi-
cally be considered second generation dot-blot assays. A
broad range of LIAs are available and they are typically used to
confirm autoantibodies previously identified by HEp-2 ANA
IIF or other screening immunoassays [119]. However, in some
laboratories, these LIAs have also been used as a screening test
for disease specific autoantibodies that are seen in SLE, SSc,
IIM, paraneoplastic, and autoimmune liver diseases [120].
There have been recent advances in partially automating
thesemultiplex LIAsmaking them somewhatmore appealing
to high throughput laboratory testing [121]. Despite their
ease of use, LIAs have some drawbacks including the lack
of sensitivity and specificity for certain autoantibodies [120,
122]. The antigen compositions of several are shown in
Table 3.
6.5. Multiplex Bead-Based Assays. Multiplex assays based on
the Luminex technology (Austin, Texas, USA) use address-
able laser beads and are therefore often referred to as ALBIA
(addressable laser bead immunoassays) [9]. Today, several
commercial ALBIA kits are available for the detection of
autoantibodies to a variety of autoantigens [83, 85, 123–130].
First generation ALBIAs showed polyreactivity which was
caused by nonspecific binding to the beads [131]. Second
generation assays showed significant reduced polyreactivity
and thus higher specificity [131]. In 2007, a multiplex test for
the detection of ANAwas compared to ANA IIF and different
ELISA assays. 7/87 (7.4%) of healthy donors were positive,
6/7 showed a speckled, and 1/7 a nucleolar staining pattern
[85]. Similar to LIAs, the number of antigens and the antigen
compositions of these bead-based arrays significantly vary
and are shown in Table 3.
6.6. Other ANA Tests. Additional methods have been devel-
oped for automated ANA detection [84, 108, 132–139]. In
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1999, a fully automated ANA screening assay (COBAS Core
HEp2 ANA EIA; Roche Diagnostics, Mannheim, Germany)
was developed and evaluated. The performance evaluation
studies showed promising results but were inclusive in the
conclusion. One study shows that the new assay is superior
to the ANA IIF as analyzed by ROC analysis [138]. However,
this finding could not be confirmed in a second independent
analysis [133]. Six years later, the first-automated chemilu-
minescent immunoassay (CIA) for the detection of ANA
(LIAISON ANA screen, DiaSorin) was evaluated in two cen-
ters yielding a good positive (79.5%) and negative agreement
(91.2%) when the LIAISONANA screen was compared to the
ANA IIF test (Bio-Rad) [140]. A recent study using this assay
showedANAprevalence compatible with the expected values
of theANA IIF test [42].Onlymoderate agreementwas found
between IIF and a multiplex assay based on the ALBIA. The
majority of ANA IIF positive and multiplex ANA negative
sera were also positive by an ANA ELISA utilizing nuclear
extracts [129]. In addition, several other methods have been
developed for ANA testing, but are not widely used in clinical
practice. In 2009, a novel method for quantitative ANA
measurement using near-infrared imagingwas also described
[141]. Furthermore, a novel microbead-based ELISA system
using fluorescence-coded immobilized microbeads on the
AKLIDIS system has been described [142]. Similar to the
ALBIA, but using nanobarcodes for the bead identification,
the Ultraplex system [143] was used to screen simultaneously
for nine ANA autoantibodies, requiring significantly less
labor and fewer reagents, with performance equivalent to
existing gold-standard methods.
Several publications have described protein arrays on
planar solid phase surfaces for the detection of autoanti-
bodies to a wide range of viral proteins and autoantigens
[144, 145] bound to a variety of surfaces [146]. However,
these immunoassays are still not used in routine diagnostic
laboratories.
More recently novel “ANA” screening assays have been
developed on fully automated closed systems such as the
Phadia (Thermo Fisher, Freiburg, Germany) or the BIO-
FLASH System (INOVA, San Diego, USA) [147]. The EliA
CTD Screen (Thermo Fisher) has been evaluated in several
studies, two of which have been published in peer-reviewed
journals [28, 148]. The first study showed satisfactory results
for anti-ribosomal P, anti-PM/Scl, anti-Mi-2, and anti-PCNA
antibodies. However, the sensitivity for anti-fibrillarin and
anti-RNA Pol III antibodies was rather limited [148]. In
the second study, the CTD screen was compared to the
ANA HEp-2000 method [29]. Additionally, the QUANTA
Flash CTD Screen Plus (on BIO-FLASH) was evaluated and
shown to exhibit good sensitivity in different SARD [149].
However, further studies are needed to establish the clinical
performance characteristics of the novel assays.
7. Quality Aspects, Standardization, and
Reference Sera
For the development and quality assurance of autoantibody
assays a broad range of international reference samples are
mandatory [150, 151]. Consequently, an ANA and related
autoantibody reference serum panel was established and
is now available through the Center for Disease Control
and Prevention in Atlanta, USA [152–155]. Initially, this
panel of sera was used to standardize ANA IIF tests and
to define staining patterns, but eventually, this panel was
used to evaluate the performance of different autoantibody
immunoassays [152]. In 2000, another ANA reference serum
panel became available through the Association of Medical
Laboratory Immunologists (AMLI) [156]. However, only a
few studies used these samples for their investigations [157].
The first international standard for ANA became available in
1990 [158]. However, the number of international reference
sera is limited and not all autoantibodies are represented by
the available serum panels [150]. Furthermore, for screening
assays, monospecific samples for each antigen are required to
ensure the presence of all antigens in sufficient quantity and
quality.
Different committees and organizations were formed
who worked to achieve a better standardized approach to
autoantibody testing [150, 159, 160] including the Interna-
tionalUnion of Immunology Specialties (IUIS)Autoantibody
Standardization Committee (http://asc.dental.ufl.edu/home
.html#text), the European Autoimmunity Stand-ardisation
Initiative (EASI) [http://www.easi-network.com/], and the
Working Group on Harmonization of Autoantibody Tests
(WG-HAT) in the framework of the International Federation
of Clinical Chemistry and Laboratory Medicine [http://www
.ifcc.org/ifcc-scientific-division/sd-working-groups/harmo-
onisation-of-autoantibody-tests-wg-hat/]. Despite signifi-
cant efforts to standardize autoantibody tests [152, 161] and
evidence that these groups are now working more closely
together, [21] significant variations still exist.
8. Conclusions
(i) Performance data (including LRs) of themethod used
to detect ANA and appropriate explanation should be
made available to the clinician.
(ii) ANA test results are only a portion of the information
that aids in the diagnosis of systemic autoimmune dis-
eases and are an adjunct to the clinician’s diagnostic
repertoire.
(iii) Both IIF on HEp-2 cells and solid phase immunoas-
says have their individual advantages and limitations.
(iv) Standardized nomenclature of diseases and associated
autoantibodies is an important goal for immediate
consideration by advisory groups.
9. Future Perspectives
Despite significant evolution and improvements in ANA
and related autoantibody testing, including the arrival of
novel and promising technologies, several limitations still
persist and need to be addressed. First, the terminology
and nomenclature used to identify and refer to various
autoantibodies need to be standardized. Second, the clas-
sification criteria and nomenclature of individual SARD
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and related autoimmune diseases must continue to evolve
and keep abreast of biomarker identification. Third, the
corresponding immunoassays and diagnostic platforms used
for the various clinical applications need to be based on
standardized reference samples of defined specificities. This
possibility could include the development and validation of
disease specific screening assays (i.e., SLE Screen, SSc Screen)
on solid phase technologies. Fourth, a clearly defined strategy
needs to be developed to facilitate clinicians and laboratory
scientists alike becoming more familiar with and be able
to intelligently use objective interpretation of autoantibody
results through an understanding of ROCs and LRs. Lastly,
diagnostic algorithms need to be adjusted to the clinical
and laboratory setting considering the referral pattern, the
sample testing volume, and health economic aspects (i.e.,
reimbursement).
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